On January 8, 2025, 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) shared in a press release that it has successfully enrolled the first patient in the NCT06478641 expanded access clinical study. This study focuses on confirming the effectiveness of tafenoquine in treating patients with persistent babesiosis who have not responded to standard care and are […]